Yes, there are some positive results and the rGBM patient population is cautiously optimistic. There are not a lot of options for this population so I think they are hoping that VB-111 is the first (of many) that can effectively help them.
Avastin is widely used but even on its website, it says, "The effectiveness of Avastin in rGBM is based on tumor response. Currently, no data have shown whether or not Avastin improves disease-related symptoms or survival in people with rGBM."
VB-111 will be a huge drug for these folks if phase 3 validates what prior trials have indicated.
News 
Market Data 
Discover 
